LMR Partners’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$30.2K Hold
500,000
﹤0.01% 1332
2025
Q4
$93.7K Hold
500,000
﹤0.01% 1352
2025
Q3
$109K Hold
500,000
﹤0.01% 1275
2025
Q2
$60.1K Hold
500,000
﹤0.01% 1207
2025
Q1
$65K Buy
+500,000
New +$70.2K ﹤0.01% 1180

Other funds holding DMAAR

LMR Partners's DMAAR Position: Q1 2026 in Review

LMR Partners held its Drugs Made In America Acquisition Corp Rights (DMAAR) position steady in Q1 2026 at 500,000 shares worth $30.2K. The position accounts for ﹤0.01% of the portfolio, ranked #1332.

LMR Partners first reported a position in DMAAR in Q1 2025 and has held it in 5 quarters since. The position peaked at $109K in Q3 2025. 35 funds tracked by Wall St. Rank hold DMAAR as of Q1 2026.

  • LMR Partners held 500,000 shares of Drugs Made In America Acquisition Corp Rights worth $30.2K as of Q1 2026.
  • LMR Partners left its Drugs Made In America Acquisition Corp Rights share count unchanged in Q1 2026.
  • Drugs Made In America Acquisition Corp Rights made up ﹤0.01% of LMR Partners's portfolio in Q1 2026, its #1332 holding.
  • LMR Partners first reported a position in Drugs Made In America Acquisition Corp Rights in Q1 2025 and has held it in 5 quarters since.
  • LMR Partners's Drugs Made In America Acquisition Corp Rights position peaked at $109K in Q3 2025.
  • 35 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q1 2026.

Based on LMR Partners's 13F filing for Q1 2026, filed 15 May 2026.